{"schema_version":"secwatch.filing_event.v1","accession":"0001563880-25-000005","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.363212+00:00","generated_at":"2026-05-17T11:08:42.562461+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Trevi Therapeutics CFO Lisa Delfini to depart Aug 22; CEO to serve as interim principal financial officer","bullets":["CFO Lisa Delfini will resign effective August 22, 2025; departure is not due to any disagreement with the company.","CEO Jennifer L. Good will serve as interim principal financial officer until a permanent CFO is appointed.","Delfini will receive separation benefits under the Executive Separation Benefits and Retention Plan, subject to a severance and release agreement.","No details provided on search for permanent CFO or timeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001563880-25-000005","json":"https://secwatch.observer/filing/0001563880-25-000005.json","markdown":"https://secwatch.observer/filing/0001563880-25-000005.md","text":"https://secwatch.observer/filing/0001563880-25-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000156388025000005/0001563880-25-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000156388025000005/trvi-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:08:42.562461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}